Sponsor study identifier
observational
621
1 country
1
Study Start
July 1, 2022
Actual (reported)Primary Completion
July 31, 2022
Actual (reported)Study Completion
July 31, 2022
Actual (reported)The purpose of this study is to explore the inflammatory biomarkers for the diagnosis of obstetric posterior reversible encephalopathy syndrome.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 16, 2022
Actual (reported)June 27, 2022
Actual (reported)July 1, 2022
Actual (reported)July 31, 2022
Actual (reported)July 31, 2022
Actual (reported)inflammatory biomarkers
The values of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio will be measured.
Inflammatory biomarkers were collected within 1 day after the onset of symptoms.
cranial Imaging
According to the cranial Imaging, PE or E patients were grouped into PRES group (typical features presence of vasogenic edema in the white matter of the portions of both cerebral hemispheres) and NOT-PRES group (imaging findings were normal).
Cranial Imaging was examined within 3 days after the onset of symptoms, such as s headaches, visual changes, seizures, consciousness impairment.
other biochemical parameters
biochemical parameters were collected within 1 week of the hospital stay.
Blood Pressure(BP)
The BP of patients was obtained within 1hour after the onset of symptoms.
pregnancy outcomes
The pregnancy outcomes will record immediately when the patients deliver.
patients in PE or E with PRES
patients in PE or E without PRES
According to the Diagnostic criteria of PRES, all the patients grouped into two groups.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Pregnant Women diagnosed with PE or E.
Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510150, China
Dunjin Chen
The Third Affiliated Hospital of Guangzhou Medical University
621 participants (actual enrollment reported by the registry).
First Submitted
June 16, 2022
First Posted
June 27, 2022
Study Start
July 1, 2022
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
July 31, 2022
Actual (reported)Study Completion
July 31, 2022
Actual (reported)Last Updated
August 3, 2022
Record last verified: 2022-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: